Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

What this Trial Is About

Researchers are investigating the immunobiology of relapses in Acute Myeloid Leukemia (AML) following allogeneic hematopoietic stem cell transplantation (HSCT). This observational study aims to analyze disease recurrence mechanisms to help develop guidelines and personalized treatment plans for patients. The study is both retrospective and prospective, involving multiple centers, and does not involve any experimental drugs or diagnostic procedures beyond routine clinical practice. Participants include adult patients with AML who experience relapse after allogeneic HSCT from family or unrelated donors. The study collects data and biological samples during standard clinical care without any intervention, focusing on understanding the role of the tumor microenvironment and gene expression changes in relapse. The study promotes standardizing therapeutic management and supports future innovative clinical studies. During the study, researchers will gather clinical data and biological samples alongside routine care. They will evaluate progression-free survival from transplant infusion until disease progression or death, monitored for up to 20 years. The study involves no additional treatments or procedures beyond usual care, aiming to improve understanding of relapse to enhance patient survival through better-targeted therapies.

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways